Cometriq and Diclofenac Sodium
Determining the interaction of Cometriq and Diclofenac Sodium and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using cabozantinib together with diclofenac may increase the risk of bleeding. In clinical studies, treatment with cabozantinib alone has been associated with severe and sometimes fatal hemorrhage. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as dizziness; lightheadedness; red or black, tarry stools; coughing up or vomiting fresh or dried blood that looks like coffee grounds; severe headache; and weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with cabozantinib is associated with severe, sometimes fatal hemorrhage including hemoptysis and gastrointestinal hemorrhage. In clinical trials, the incidence of Grade 3 hemorrhagic events was higher in patients receiving cabozantinib compared with placebo (3% vs. 1%).
MANAGEMENT: Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with cabozantinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
- "Product Information. Cometriq (cabozantinib)." Exelixis Inc, S San Francisco, CA.
Generic Name: cabozantinib
Brand name: Cometriq, Cabometyx
Synonyms: n.a.
Generic Name: diclofenac
Brand name: Cambia, Cataflam, Voltaren-XR, Zipsor, Zorvolex, Voltaren, Dyloject, also Cambia
Synonyms: Diclofenac, Diclofenac (Systemic)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Cometriq-Diclofenac Sodium topical
- Cometriq-Diclofenac Sodium Topical Solution
- Cometriq-Diclofenac Tablets
- Cometriq-Diclofenac topical
- Cometriq-Diclofenac Topical Patch
- Cometriq-Diclofenac Topical Solution
- Diclofenac Sodium-Comfort Pac w/Tizanidine
- Diclofenac Sodium-Comfort Pac with Cyclobenzaprine
- Diclofenac Sodium-Comfrey
- Diclofenac Sodium-Commit
- Diclofenac Sodium-Compazine
- Diclofenac Sodium-Compazine Rectal